Location:
UBC Hospital
Supervisor:
Jacqueline Quandt
December 1, 2022
Location:
UBC Hospital
Supervisor:
Jacqueline Quandt
December 1, 2022
Location:
BC Children’s Hospital Research Institute
Supervisor:
Bruce Verchere
December 1, 2022
Location:
UBC, Djavad Mowafaghian Centre for Brain Health
Supervisor:
Cheryl Wellington
December 1, 2022
Location:
St. Paul’s Hospital
Supervisor:
Ying Wang
December 1, 2022
Academic Rank:
Affiliation(s):
Location:
St. Paul’s Hospital
Supervisor:
Ying Wang
December 1, 2022
Location:
BC Children’s Hospital Research Institute
Supervisor:
Kirk Schultz
December 1, 2022
Location:
UBC
Supervisor:
Babak Shadgan/Donald Anderson
December 1, 2022
Academic Rank:
Affiliation(s):
Location:
BC Children’s Hospital Research Institute
Supervisor:
Angela Devlin
December 1, 2022
Location:
BC Children’s Hospital Research Institute
Supervisor:
Ramon Klein Geltink
December 1, 2022
Location:
BC Children’s Hospital Research Institute
Supervisor:
Ramon Klein Geltink
December 1, 2022
Location:
BC Children’s Hospital Research Institute
Supervisor:
Ramon Klein Geltink
December 1, 2022
Location:
BCCDC
Supervisor:
Inna Sekirov/Mel Krajden
December 1, 2022
Location:
BC Children’s Hospital Research Institute
Supervisor:
Bruce Verchere
December 1, 2022
Location:
UBC
Supervisor:
Ed Pryzdial
December 1, 2022
Academic Rank:
Affiliation(s):
Location:
UBC
Supervisor:
Cheryl Wellington
December 1, 2022
Location:
BC Children’s Hospital Research Institute
Supervisor:
Philipp Lange
December 1, 2022
Dr.
PhD
e-mail:
Lab Website
Academic Rank:
Professor, UBC, Distinguished Scientist
Affiliation(s):
BC Cancer Research Centre
Location:
Terry Fox Laboratory
Dr. Takei received his PhD from the University of British Columbia (UBC) and completed postdoctoral training in Cambridge, England. He then returned to UBC to lead his own laboratory. He has been working on innate lymphocytes for over 30 years. From 1990 to 2010, he mainly worked on natural killer (NK) cell receptors for MHC class I and regulation of NK cell functions and development. In 2010, he found a unique lymphocyte population, which is now termed group 2 innate lymphoid cell (ILC2), in mouse lungs. He showed that lung ILC2s play a key role in allergic lung inflammation. He is currently investigating the regulation of ILC2 functions and functional and developmental relationship between ILC2s and other lymphocytes.
Our current researches focus on innate lymphoid cells in mouse lungs. We are investigating the regulation of group 2 innate lymphoid cell functions, their interaction with other cells and their role in allergic lung inflammation.
December 1, 2022
Dr.
Academic Rank:
Clinical Associate Professor, UBC, Environmental Public Health Microbiologist at Provincial Health Services Authority and University of British Columbia
Affiliation(s):
BCCDC
Location:
BCCDC
Dr. Natalie Prystajecky is an Environmental Microbiologist at the BCCDC Public Health Laboratory and a Clinical Associate Professor in Pathology and Laboratory Medicine at the University of British Columbia. Her work is at the intersect of environmental exposures (food and water) and clinical outcomes. She uses emerging technologies to improve routine surveillance and outbreak investigations for foodborne and waterborne pathogens. she has received grant funding from the BCCDC Foundation, Canadian Water Network, NSERC, Genome BC and Genome Canada. Her current research interests include development of new water quality tests using metagenomics, targeted resequencing of wetland sediments to study the emergence of avian influenza strains and whole genome sequencing of Giardia and Salmonella. She is keen to promote the translation of research methods to routine testing in diagnostic and reference laboratories.
Specialties: Public health, environmental microbiology, drinking water, food quality, genomics, molecular diagnostics
December 1, 2022
Dr.
PhD
e-mail:
Lab Website
Academic Rank:
Assistant Professor, Department of Pathology and Laboratory Medicine
Affiliation(s):
BC Children’s Hospital Research Institute
Location:
BC Children’s Hospital Research Institute
Ramon I. Klein Geltink currently runs a research lab at UBC/ BC Children’s Hospital Research Institute. The Klein Geltink lab does research in Metabolism, Immunology, Cell Biology and Molecular Biology. Their most recent publication is ‘The metabolic tug of war between HIV and T cells’.
My research program aims to better understand how the immune system can be used to treat childhood diseases. In children with cancer, the immune system is no longer able to rid the body of cancerous cells. In children with autoimmune diseases the immune system gets rid of healthy cells of the body. We are particularly interested in the metabolism of immune cells. Metabolism consists of all the chemical processes that occur within a living organism that maintain life. In immune cells, this means that building blocks (metabolites) need to be brought in to allow the duplication of a cell by making all crucial parts of new cells. In fast growing immune cells this is especially demanding, since they need to duplicate themselves very rapidly to protect against attacks on the normal function of our bodies by, for instance, infections or cancer. This requires a variety of building blocks, and a lot of energy. For this process, cells can acquire these building blocks from their environment, or make them via intricate biochemical pathways. When the right building blocks are not available, immune cells fail to increase in numbers and cannot perform their job.
We use biochemical and metabolomic techniques to understand what fuel is needed for immune cell function, and how immune cells sense the fuel that is available in their environment.
By closely collaborating with Clinicians and Clinician scientists at BCCHR we are aiming to apply the findings to design better treatments for children with immune related diseases.
December 1, 2022
Dr.
MD, PhD, FRCPC
e-mail:
Academic Rank:
Clinical Assistant Professor, UBC , Medical Microbiologist, BC Centre for Disease Control
Affiliation(s):
BC Centre for Disease Control
Location:
BC Centre for Disease Control
Dr. Inna Sekirov is a medical microbiologist in the Public Health Laboratory (PHL) at BCCDC and the program head for the Tuberculosis (TB)/Mycobacteriology Laboratory. She is also a clinical assistant professor at UBC.
To date, Dr. Birol’s team has accelerated research with over 140 publications, which have practical applications in both ecosystems and human biology, including medical genomics. As of 2018, he is listed among the top 1% cited scientist in the world by Clarivate Analytics in the Cross-Field category.
Dr. Sekirov’s interests include the public health-related aspects of medical microbiology, clinical applications of microbial genomics and tuberculosis (TB)/mycobacteriology diagnostic methods. Since the start of the SARS-CoV-2 pandemic, she has been involved in research into the humoral responses post-SARS-CoV-2 infection and vaccination, as well as the role of the ACE2 receptor in SARS-CoV-2 infection.
December 1, 2022
Dr.
MSc, PhD
e-mail:
Lab Website
Academic Rank:
Assistant Professor, Dept of Pathology & Laboratory Medicine
Affiliation(s):
BC Cancer Research Centre
Location:
BC Cancer Research Centre
Dr. Yongjin Park is a principal investigator (Scientist) in the Department of Molecular Oncology at BC Cancer Research, part of the Provincial Health Services Authority. Dr. Park earned his Bachelors of Science in Biology and Computer science and Engineering from Seoul National University in South Korea in 2006. His Interests in biology and computer science in his undergraduate degree lead him to a Masters of Science in Computational Biology from Carnegie Mellon University in Pennsylvania graduating in 2008. From there Dr. Park ventured to Maryland where he earned his PhD in the number one ranked Biomedical Engineering program in the U.S. from Johns Hopkins University in 2014. He completed his post doctorate at Massachusetts Institute of Technology’s Computer Science and Artificial Intelligence Laboratory, and remained there until Dr. Park joined us at BC Cancer.
He is also an Assistant professor in the Department of Pathology & Laboratory Medicine and the Department of Statistics at the University of British Columbia (UBC). He leads an interdisciplinary team of young scholars consisting of statisticians, computer scientists, and bioinformaticians. His research primarily focuses on developing scalable probabilistic inference methods to elucidate hidden causal mechanisms of human diseases, such as cancer and other common/complex disorders.
Our lab in BC Cancer Research conducts causal inference research to understand the mechanisms of complex disease development and progression using machine learning and data science. We develop causal inference and machine learning methods widely applicable in single-cell genomics, multi-omics data integration, and statistical genetics research. We apply our computational methods to large regulatory genomics and single-cell transcriptomics data generated by international consortia, such as NIH ENCODE and GTEx, Human Cell Atlas, and Tabula Muris/Sapiens (Chan-Zuckerberg BioHub). We are also privileged to contribute to single-cell data analysis in collaborations locally with the experimental labs at BC Cancer Research Institute, including Dr. Samuel Aparicio, Dr. Poul Sorensen, and Dr. Ramon Klein Geltink.
Our lab is uniquely situated across multiple disciplines: single-cell genomics, statistical genetics, causal inference and machine learning. Through this vantage point, not only do we push forward the frontiers of machine learning research in biology, but our research program also seeks to identify uncharted directions in computational biology research. Our computational research involves reproducible, efficient, and widely-applicable software development. We have rich experience in scientific computing and machine learning before and after the deep learning renaissance. If needed, instead of being confined by existing tools and libraries, our computational team can initiate research from a low-level programming language
December 1, 2022
Dr.
MD, PhD, FRCPC
e-mail:
Lab Website
Academic Rank:
Professor and Department Head, Pathology and Laboratory Medicine
Affiliation(s):
BC Cancer Research Centre
Location:
BC Cancer Research Centre
Grow up in a small village of mainland China, Dr. Zu-hua Gao obtained his Medical degree from Qingdao Medical College, Master degree from Harbin Medical University, and PhD degree from Peking Union Medical College. Dr. Gao received his post-doctoral fellowship training at the Johns Hopkins Hospital, pathology residency training at Dalhousie University, and subspecialty pathology fellowship at the University of Chicago. Dr. Gao had been the Division Head of Anatomical Pathology and Cytopathology at the University of Calgary and Calgary Laboratory Services between 2007-2011. Between September 2012 and November 2021, Dr. Gao has been the Chair and Chief of the Department of Pathology at McGill University. Since 2019, Dr. Gao has been the President of Canadian Chairs of Pathology and Laboratory Medicine. In 2017, Dr. Gao became a Fellow of the Royal Society of Medicine (London UK). In 2019, Dr. Gao became a Fellow of the Canadian Academy of Health Sciences. Dr. Gao is currently the Professor and Head of the Department of Pathology and Laboratory Medicine at the University of British Columbia.
Dr. Gao received many awards including the Junior Scientist Award at CAP-ACP, the Dalhousie Medical Foundation award, the McGill University Health Center Foundation award, etc.
Click on http://www.ncbi.nlm.nih.gov/pubmed/?term=gao%2C+zu+hua to see my current publications list
Dr. Gao’s research focuses on the molecular mechanism of colon cancer metastasis and the prognostic and predictive biomarkers for pancreatic ductal adenocarcinoma. As a research scientist, Dr. Gao published 175 peer-reviewed articles, over 75 abstracts and meeting presentations, and 25 invited speeches at national and international venues.
Clinical Service
As a surgical pathologist, Dr. Gao’s clinical expertise is gastrointestinal and liver pathology.
December 1, 2022
Academic Rank:
Professor at the University of British Columbia, Department of Medical Genetics; Distinguished Scientist at Canada’s Michael Smith Genome Sciences Centre
Affiliation(s):
Michael Smith Genome Sciences Centre
Location:
Canada’s Michael Smith Genome Sciences Centre, Echelon Technology
Dr. Inanc Birol is a distinguished scientist at Canada’s Michael Smith Genome Sciences Centre, a professor at the University of British Columbia (UBC), Department of Medical Genetics, an associate member of the Departments of Computer Science, and Pathology and Laboratory Medicine at UBC, and an adjunct scientist at BC Centre for Disease Control. Previously, he held research faculty and associate positions at Simon Fraser University, Illinois Institute of Technology and CERN – the latter, a knowledge centre for understanding the universe and home to the largest particle physics laboratory in the world.
To date, Dr. Birol’s team has accelerated research with over 140 publications, which have practical applications in both ecosystems and human biology, including medical genomics. As of 2018, he is listed among the top 1% cited scientist in the world by Clarivate Analytics in the Cross-Field category.
Dr. Birol’s research interests include the analysis of data from modern sequencing instruments to study genomes and transcriptomes of model species and humans. He directs the Bioinformatics Technology Lab, which develops bioinformatics tools for de novo sequence assembly, sequence mapping, downstream data analysis and visualization. He also directs a wet lab at BC Centre for Disease Control to study antimicrobial resistance and to develop novel strategies as alternatives to conventional antibiotics.
December 1, 2022
Dr.
MD, MSc, PhD, FSPIE
e-mail:
Lab Website
Academic Rank:
Assistant Professor in the Department of Orthopaedics
Affiliation(s):
ICORD, VCH Research Institute
Location:
ICORD
Dr. Babak Shadgan is a Michael Smith Foundation for Health Research Scholar, an assistant professor in the Department of Orthopaedics at the University of British Columbia (UBC), an associate faculty member at the UBC School of Biomedical Engineering and a principal investigator at ICORD, where he is directing the Implantable Biosensing Laboratory.
Dr. Shadgan is a medical doctor specialized in sports and exercise medicine, graduated from the Queen Mary College of the University of London, with a PhD in experimental medicine from UBC. He completed a fellowship on NIRS-Diffused Optical Tomography at Martinos Center for Biomedical Imaging of MIT/Harvard University. His post-doctoral fellowship at UBC was focused on remote optical monitoring of muscle dysfunction in people with spinal cord injury. With more than two decades of medical practice and research, Dr. Shadgan has developed a specific knowledge in clinical applications of biosensing technologies with a unique integrated transitional bedside-to-bench and bench-to-bedside approach. He is actively working on design and development of novel wearable and implantable biosensors and their applications in health and diseases.
Dr. Shadgan is a Fellow member, an instructor and a conference chair at the International Society for Optics and Photonics. He is an advocator of multidisciplinary networking and collaborations between biomedical engineering and clinical scientists for innovative and applied technology development in medicine.
As an Olympic sports physician leading the Medical & Anti-Doping Commission of the International Federation of Olympic Styles Wrestling (UWW), Dr. Shadgan has been serving elite athletes at world championships and Olympic Games since 2002. He is also actively working on design and development of novel wearable sport monitoring biosensors and their applications in sports and exercise medicine.
December 1, 2022
Dr.
MD, PhD, FRCSC
e-mail:
Lab Website
Academic Rank:
Professor, Department of Orthopaedics, Faculty of Medicine, University of British Columbia, Canada Research Chair in Spinal Cord Injury, Spine Surgeon, Vancouver Spine Program, Vancouver General Hospital
Affiliation(s):
ICORD, VCH Research Institute
Location:
ICORD
Dr. Kwon is a surgeon-scientist with advanced training in spine surgery and also a PhD in neuroscience. He is a Professor in the UBC Department of Orthopaedics. As an attending orthopaedic spine surgeon at Vancouver General Hospital his practice is focused on the management of adult spine trauma, spinal cord injuries, and non-traumatic conditions such as spine infection, deformity, and degeneration. As a neuroscientist and Principal Investigator at ICORD, Dr. Kwon runs an active basic/translational research laboratory. Dr. Kwon is currently also serving as the Associate Director, Clinical Research, for ICORD and is the Director of Research for the Vancouver Spine Research Program.
Dr. Kwon’s primary research interest is in spinal cord injury. During his residency, he met many young patients on the spinal cord unit whose lives had been devastated by SCI; this motivated him to pursue a career in spine surgery and a PhD in neuroscience. Now, as a surgeon-scientist, his research interests in SCI span the translational continuum from basic bench research all the way to clinical trials. His research program is best characterized by “bedside back to bench” and “bench to bedside” bi-directional translation.
Currently, Dr. Kwon is leading a North American clinical trial in acute SCI to improve guidelines for the management of patients in the early stages of their injury and also to establish biomarkers of injury by providing a more complete picture of the pathophysiology of acute human SCI. His interest in the human pathophysiology of SCI has led him to establish the International Spinal Cord Injury Biobank (ISCIB). In the laboratory, he has developed new models to facilitate the preclinical evaluation of novel therapeutic strategies and to also better understand clinical observations from acute SCI patients.
Dr. Kwon loves working with ICORD because of the multidisciplinary interface between science and medicine. He enjoys the ease with which his research can translate from “bench-to-bedside” and “bedside back to bench” with ICORD situated right on the campus of Vancouver General Hospital, the provincial referral centre for all acute spinal cord injuries in British Columbia.
December 1, 2022
Academic Rank:
Assistant Professor, Department of Medicine, University of British Columbia
Affiliation(s):
BC Cancer Research Centre
Location:
BC Cancer Research Centre
Clinical and Research Roles
Dr. Scott is an Assistant Professor in the Department of Medicine at the University of British Columbia and a Scientist in the Department of Lymphoid Cancer Research (BC Cancer). He gained his MBChB/PhD from the University of Auckland, New Zealand. Following his clinical fellowships in hematology, he took up a post-doctoral fellowship at BC Cancer with Drs. Gascoyne and Connors. In 2014, he was appointed as a Clinician-Scientist at BC Cancer, receiving the inaugural BC Cancer Foundation Clinical Investigator Award. Dr. Scott’s research focusses on unravelling the determinants of treatment failure in B-cell lymphoid cancers (lymphoma and CLL) and translating this knowledge into assays to guide treatment management. He has authored over 60 peer-reviewed papers, has been an invited speaker at many conferences and receives research funding from Genome Canada, the Terry Fox Research Institute, the Lymphoma Research Foundation and the National Institutes of Health. He is the Clinical Director of BC Cancer’s Centre for Lymphoid Cancer, a member of the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) and the Translational Sciences Co-Chair of the Lymphoma Tumor Group of ECOG.
Dr. Scott’s lab focuses on discovery and development of clinically relevant biomarkers to improve disease classification and patient care. Dr. Scott is a member of the Lymphoma/Leukemia Molecular Profiling Project Consortium and is leading a large international project along with distinguished lymphoma clinicians and experts in Cancer Genomics to uncover lymphoma pathogenesis and genomic mechanisms underlying treatment failure in aggressive lymphoma. Also, Dr. Scott is co-leading a large scale applied research project funded by Genome Canada, Genome BC, Canadian Institutes of Health Research and BC Cancer Foundation to address the most significant knowledge gap in lymphoma care; the genome biology of relapsed lymphoid cancers. Dr. Scott has a strong track record of discovery of biomarkers applicable to aggressive B-cell lymphomas and is recognized as an expert in biomarkers and the tumor microenvironment of these diseases. Dr. Scott has developed prognostic and predictive biomarker assays and filed four patents to date, which reflects the true translational nature of his research.
December 1, 2022
Dr.
MD, FRCP(C), D(ABHI)
e-mail:
Lab Website
Academic Rank:
Assistant Professor, Dept of Pathology & Laboratory Medicine, UBC, Kidneys and Urinary System, VGH
Affiliation(s):
VCHRI
Location:
VCHRI
Dr. James Lan is an assistant professor jointly appointed to the Department of Pathology and Laboratory Medicine and the Division of Nephrology at University of British Columbia (UBC). He is the medical director of the Vancouver Immunology Laboratory and an active transplant nephrologist at Vancouver General Hospital. He holds leadership positions as the BC Transplant Immunology Consultant and sits on the CBS Willing to Cross Working Group, CBS National HLA Advisory committee, CBS HLA Educational Committee, CBS Kidney Policy Implementation Committee and CST Awards and Grants Committee. He is a valued member of the Genome Canada Transplant Consortium and the UBC Research Excellence Cluster for Precision Medicine in Transplantation.
Dr. Lan is the recipient of a VCHRI Mentored Clinician Scientist award and is a Michael Smith Foundation Health Scholar. He has received funding for his work from the Kidney Foundation of Canada, UBC Grants for Catalyzing Research Clusters, UBC Barbara Opperman Grant, VCHRI and the Transplant Research Foundation of BC to support the development and application of new technologies to improve donor-recipient immune compatibility. A major focus of his research aims to innovate new solutions for highly sensitized patients on the kidney waiting list.
Dr. Lan contributes to the education of future clinicians and scientists by lecturing in the Georgetown series, the American Foundation for Donation and Transplantation and the CST Fellows Symposium. He also presents regularly as an invited speaker both nationally and internationally.
Kidneys and Urinary System
December 1, 2022
Dr.
e-mail:
Academic Rank:
Associate Professor, Department of Mechanical Engineering, UBC
Affiliation(s):
Centre for Blood Research
Location:
Institute for Computing, Information and Cognitive Systems (ICICS)
Current Positions
Dr. Hongshen Ma is an associate professor in the Department of Mechanical Engineering and School of Biomedical Engineering at the University of British Columbia (UBC). He obtained his bachelor’s degree in Engineering Physics from UBC, master’s from the Media Laboratory at the Massachusetts Institute of Technology (MIT), and PhD from Electrical Engineering at MIT. Dr. Ma’s research program aims to develop new technologies to interrogate and manipulate biological systems at the cellular scale with a specific focus on cytometry and cell separation. His work include the development of microfluidic devices to analyze cell deformability and to separate cells based on deformability.
These devices are being used to analyze the loss of red blood cell deformability as a biomarker in transfusion medicine and falciparum malaria, as well as the separation of circulating tumor cells from prostate cancer patients. Dr. Ma’s research also includes the development of machine learning algorithms for image cytometry, as well as technologies for image-based cell separation and single cell sequencing.
The overarching goal of our research is the development of new technologies for medical research and treatment. Our work is enabled by advances in fabrication, measurement, and computation across a wide range of domains and length scales. Our core capabilities include microfabrication, microfluidics, instrumentation and automation, data analytics, and product development. Current research areas include 1) the development of new technologies for cell sorting, cell biomechanics, single cell sequencing, and cell migration and chemotaxis; as well as 2) the application of these technologies to study circulating tumor cells, personalize cancer therapies, assess blood quality, and expedite antimalarial drug development.
December 1, 2022
Dr.
BSc, MD (McG.), FRCPC
e-mail:
Academic Rank:
Professor, UBC, Medical Director, Public Health Serology, Provinical Health Services Laboratories, Director, BC Hepatitis Services, BC Centre for Disease Control, Laboratory Services, Associate Director, Laboratory Services, Head of Virology Section, BC Centre for Disease Control, Laboratory Services
Affiliation(s):
BC Centre for Disease Control
Location:
BC Centre for Disease Control
Dr. Mel Krajden is the medical director of the BCCDC Public Health Laboratory. He is also the medical head of hepatitis at BCCDC and is involved in the BC Hepatitis Testers Cohort.
Dr. Krajden earned his BSc and MD at McGill University (1973-80). He undertook internal medicine training at McGill University (1980-83). Afterwards, he did a fellowship in infectious diseases at Stanford University (1983-86) and completed a medical microbiology residency at the University of Toronto (1986-87).
Between 1991 and 1998, he was section head of virology and serology and an infectious diseases consultant at the Toronto Hospital (The University Health Network). In September 1998, he moved from Toronto to Vancouver, to BCCDC and UBC.
He is an adjunct scientist with Canadian Blood Services and a member of the Canadian Blood Services Scientific and Research Advisory Committee.
Dr. Krajden’s clinical research involves the integration of hepatitis prevention and care services. His laboratory research involves the application of molecular techniques to diagnose viruses, assess correlates between infection and clinical disease, use molecular techniques to monitor antiviral efficacy and track microbial infections for epidemiological purposes. He also has extensive clinical trials expertise and serve as a laboratory coordinator of industry-sponsored clinical trials.
He has been involved in various types of research domain, including hepatitis, influenza, human papillomavirus, HIV, and molecular diagnostics and phylogenetics as well as the use of linked laboratory and administrative data to help understand how to measure population-level health outcomes for policymaking.
December 1, 2022
Dr.
MD, PhD, FRCPC
e-mail:
Academic Rank:
Assistant Professor, Department of Pathology and Laboratory Medicine, Neuropathologist at VGH
Affiliation(s):
VCH Research Institute, ICORD
Location:
Vancouver General Hospital
Dr. Veronica Hirsch-Reinshagen is a consultant neuropathologist at Vancouver General Hospital and an assistant professor in UBC’s Department of Pathology and Laboratory Medicine. She attained her medical degree in Chile and her Ph.D. in neurosciences at UBC.
Her research focus is on the histopathological changes that underlie a number of central nervous system disorders including traumatic spinal cord injury. Her main research tools include histology and correlations between clinical presentation, imaging changes and pathological findings.
December 1, 2022
Dr.
PhD
e-mail:
Academic Rank:
Professor of Medicine, University of British Columbia
Affiliation(s):
UBC Centre for Blood Research
Location:
Life Sciences Centre
Current Positions
Dr. Takei received his PhD from the University of British Columbia (UBC) and completed postdoctoral training in Cambridge, England. He then returned to UBC to lead his own laboratory. He has been working on innate lymphocytes for over 30 years. From 1990 to 2010, he mainly worked on natural killer (NK) cell receptors for MHC class I and regulation of NK cell functions and development. In 2010, he found a unique lymphocyte population, which is now termed group 2 innate lymphoid cell (ILC2), in mouse lungs. He showed that lung ILC2s play a key role in allergic lung inflammation. He is currently investigating the regulation of ILC2 functions and functional and developmental relationship between ILC2s and other lymphocytes.
Defining the molecular links between coagulation and innate immunity
Throughout evolution, organisms have developed means to simultaneously contain wounds by limiting bleeding with clot formation and fighting pathogens, thereby enabling rapid healing. Disease emerges when there is unchecked activation of the innate immune and/or coagulation responses. Indeed, simultaneous excess coagulation and innate immune responses are evident in numerous diseases, including, for example, atherosclerosis, stroke, coronary heart disease and diabetes, as well as organ ischemia-reperfusion, the metabolic syndrome, and other vasculopathic disorders, such as age-related macular degeneration, and hemolytic-uremic syndrome.
With the discovery that common molecular mechanisms regulate coagulation and inflammation, the last decades have seen major progress in identifying the cellular and molecular links. However, there remain major gaps in our knowledge and new discoveries are urgently needed for the development of novel strategies to prevent and/or treat cardiovascular disease and stroke. In our lab, we characterize the interplay between coagulation and complement, seeking relevant applications to our discoveries, using pre-clinical and clinical modeling approaches.
The perplexing story of the “tumor endothelial marker”, endosialin (CD248)
Endosialin (CD248) was originally identified as a tumor endothelial marker, but is now recognized to be expressed on the surface of activated stromal cells. This multi-domain glycoprotein is only expressed under pathologic conditions. Mice that lack CD248 are less sensitive to pro-inflammatory and oncogenic stimuli. We have determined that the cytoplasmic domain of CD248 modulates intracellular signals that promote tumor growth and inflammation. Ongoing studies are designed to identify molecular mechanisms by which CD248 functions, the protein partners with which CD248 interacts, and the wider impact of changes in expression of CD248. The findings may provide novel avenues for therapeutic targeting.
December 1, 2022
Dr.
MD, FRCPC
e-mail:
Lab Website
Academic Rank:
Associate Professor, Dept of Pediatrics and Laboratory Medicine
Affiliation(s):
VCH Research Institute
Location:
VGH/VCHRI
Dr. Schaeffer is an associate professor in the Department of Pathology & Laboratory Medicine at University of British Columbia and the Head of the Division of Anatomic Pathology at Vancouver General Hospital (VGH) where he practices as a gastrointestinal pathologist. Dr. Schaeffer obtained his medical degree from the Johannes Gutenberg University of Mainz, Germany. After a residency program in Anatomical Pathology in Vancouver he completed his gastrointestinal pathology fellowship at Mount Sinai Hospital in Toronto. Dr. Schaeffer is a co-director of Pancreas Centre BC and also heads the Gastrointestinal Biobank (GIBB) at VGH. He has an active research program focusing predominately on translational research in colonic and pancreatic cancer.
December 1, 2022
Academic Rank:
Affiliation(s):
iCORD
Location:
VGH
Supervisor:
Brian Kwon
December 1, 2022
Location:
BCGSC
Supervisor:
Marianne Sadar
December 1, 2022
Location:
UBC, Djavad Mowafaghian Centre for Brain Health
Supervisor:
Cheryl Wellington
December 1, 2022
Academic Rank:
Affiliation(s):
BCCHRI
Location:
British Columbia Children’s Hospital Research Institute
Supervisor:
David Huntsman
December 1, 2022
Location:
BCCRC
Supervisor:
David Huntsman
December 1, 2022
Location:
BCGSC
Supervisor:
Marianne Sadar
December 1, 2022
Location:
BCCRC
Supervisor:
Zu-hua Gao, Helene Cote
December 1, 2022
Location:
St. Paul’s Hospital
Supervisor:
Mari Demarco
December 1, 2022
Location:
UBC CBR
Supervisor:
Jay Kizhakkedathu
December 1, 2022
Location:
UBC, CBR
Supervisor:
Dana Devine
December 1, 2022
Location:
CBR
Supervisor:
Dana Devine
December 1, 2022
Location:
Vancouver General Hospital
Supervisor:
David Granville
December 1, 2022
Location:
BCCRC
Supervisor:
Sam Aparicio
December 1, 2022
Location:
UBC, CBR
Supervisor:
Ed Pryzdial
December 1, 2022
Location:
UBC, Djavad Mowafaghian Centre for Brain Health
Supervisor:
Cheryl Wellington, Thalia Field
April 20, 2021
PALM GRADUATE PROGRAM NEWSLETTER
The first of our new PALM Graduate Program weekly newsletter was issued on Monday, April 19th, 2021 at 11:00am PDT. With this newsletter, we hope to collate in one place information relevant to graduate students in our program and their supervisors, replacing several individual emails that would otherwise be sent throughout the week. These newsletters will be issued every Monday at 11:00am, or Tuesday if Monday is a holiday.
If you would like to post something in the newsletter (or wish to give feedback), please contact the Graduate Program Coordinator, Heather Cheadle.
Archived Past Newsletters (2024):
September 18, 2017
PhD DEFENCE Friday, February 2nd, 2018
Student: Sara Saberi
Title: Dynamics of Telomere Length and Mitochondrial DNA Content in a Cohort Study of HIV-Infected and HIV-Uninfected Pregnant Women and Cell Culture Models
Time and location: 9:00am PST; Room 200 of the Graduate Student Centre (6371 Crescent Road), UBC Vancouver Point Grey Campus
Supervisor: Dr. Helene Cote
ABSTRACT
Globally, women constitute around 50% of HIV-infected individuals. While mother-to child transmission accounts for 90% of new HIV infections among children, combination antiretroviral therapy (cART) reduces the risk from 25% to <2%. Treatment guidelines now promote lifelong cART for all persons living with HIV. This implies that more women will be conceiving on cART and exposing their unborn child over a longer period. Nucleoside reverse transcriptase inhibitors can have off target effects. These drugs can inhibit reverse transcriptase activity of telomerase, which could lead to a shortening of leukocyte telomere length (LTL). LTL has been described as a marker of cellular aging and a predictor of age-related diseases over time. Several antiretrovirals (ARVs) can exert mitochondrial toxicity, leading to mitochondrial dysfunction. The overarching hypothesis of my research was that LTL and mitochondrial DNA (mtDNA) content would be affected by cART in clinical and cell culture samples.
I measured LTL in blood samples collected from 64 HIV-infected and 41 HIVuninfected women at three visits during pregnancy using monochromatic multiplex quantitative polymerase chain reaction. CART treatment status during pregnancy was not associated with shorter LTL. However, smoking throughout pregnancy and receiving a ritonavir-boosted protease inhibitor regimen were independently associated with shorter LTL among HIV-infected women. Whether these reflect telomere attrition or redistribution of cellular subsets is unclear.
In clinical studies, it is challenging to distinguish between the effects of HIV vs. those of cART. I used cultured placental and T-lymphoblast cells to study the changes in mtDNA content following either short term exposure to individual ARVs at increasing concentrations, or longer term exposure (21 days) to cART regimens at 1×Cmax, (maximum concentration) prior to returning the cells to cART-free medium for ten more days, to allow recovery/repair. Most ARVs and cART studied here induced increased mtDNA content, postulated to reflect mitochondria biogenesis in response to cellular stresses and/or damage, something that could promote the clonal expansion of mtDNA mutations. However, changes in mtDNA content in response to ARV exposure can be both bidirectional and cell-specific; and appear to be reversible. Mitochondria morphological changes were suggestive of increased mitophagy to preserve mitochondrial health.
September 18, 2017
PhD DEFENCE Friday, July 27th, 2018
Student: Tina (Tianqing) Yang
Title: Proteomic Investigation of Protein Function and Regulatory Pathways in Cancer
Time and location: 9:15 am PST; Room 202, Anthropology and Sociology Building, 6303 NW Marine Drive, UBC Point Grey Campus
Supervisor: Dr. Poul Sorensen
ABSTRACT
Proteins are essential components of the cell and the organism, fulfilling diverse functions that are often dysregulated in cancer. As many proteins act as a component of multisubunit complexes and intricate pathways, understanding how these complexes and pathways function and become dysregulated is important to the understanding of tumour initiation, progression, and resistance to treatment. The rapidly-advancing field of proteomics has made important contributions to basic cancer research, due to its applicability to the study of various aspects of protein biology in a systemic way. The aim of this thesis was to apply state-of-the-art proteomics techniques to different aspects of basic cancer research; namely, to identify potential mechanisms of mTOR inhibitor resistance, and to uncover novel functions of the tumour suppressor HACE1.
Firstly, SILAC (stable isotope labelling by amino acids in cell culture) and Click-pulse-SILAC were used to comprehensively characterize cellular responses to the mTORC1/2 inhibitor Torin1.
Large-scale data with extensive coverage of the proteome was generated, from which data analysis identified RTK (receptor tyrosine kinase) upregulation as an important phenomenon in response to Torin1 that was at least in part affected by the transcriptional coactivator p300. p300 silencing by siRNA attenuated RTK upregulation as well as MAPK/PI3K signalling, and co-treatment of cells with Torin1 and the p300 inhibitor C646 enhanced the ability of Torin1 to inhibit cell proliferation. Secondly, the proximity labelling proteomics approach, APEX-MS, was used to capture potential interactors and substrates of the E3 ubiquitin ligase HACE1 (HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1), which has tumour suppressor activity in a number of contexts. Various data analysis and extraction approaches identified several novel pathways in which HACE1 may be involved, and characterized the novel interactor and substrate of HACE1, HGS (hepatocyte growth factor-regulated tyrosine kinase substrate). Collectively, these studies demonstrate the versatility of proteomics-based approaches in studying aspects of cancer biology and the diverse kinds of data that can be extracted from proteomic analyses.
October 28, 2016
The Annual Pathology Arts Gala will be held on Friday November 4 from 7:00pm-10:30pm at the Thea Koerner House Ballroom.
Pathology Arts Gala is a night to celebrate performers and artists in the Department of Pathology and Laboratory Medicine. This year’s line-up will include performances from students, faculty, and staff with musical, dancing, and vocal skills. On display will also include pieces by talented artists ranging from photography to stained glass.
You can purchase tickets from the following people (or contact us at pasa@pathology.ubc.ca):
BCCRC: Brennan Wadsworth (bwadsworth@bccrc.ca)
Ada Young (ayoung@bccrc.ca)
Yang Xia (xiazcy@gmail.com)
VGH: Fraser Muir (frasergmuir@gmail.com)
CFRI: Karen Simmons (karen.simmons@alumni.ubc.ca)
Lisa Decotret (lisa.decotret@alumni.ubc.ca)
Thyrza Toledo (thyrzamay@alumni.ubc.ca)
UBC: Emily Button (ebbutton@mail.ubc.ca)
Marta Salvador (so.marta184@gmail.com)
Tickets will also be sold at Graduate Student Seminar on November 1st!
Hurry before tickets sell out!
Pathology Student Association
Graduate Student Society Affiliate Organization
Pasa@pathology.ubc.ca | www.facebook.com/UBCPaSA
January 4, 2016
Once again, one of our MD/PhD students affiliated with the PALM graduate program has won a Vanier scholarship. These are highly competitive awards funded by the Government of Canada. The Vanier Canada Graduate Scholarships program “attracts and retains world-class doctoral students and helps establish Canada as a global centre of excellence in research and higher learning”. It is truly an honor for Frank and our program to have his achievements recognized in this manner. Frank is a Year 3 student in the combined MD/PhD Program. His research supervisor is Dr. Ed Pryzdial at the Centre for Blood Research, and his hosting department is Pathology and Laboratory Medicine.
Frank’s research focus is studying the mechanism of how blood clots are dissolved, a process known as fibrinolysis. Tissue plasminogen activator (tPA), the physiological initiator of fibrinolysis, has been used as a vital “clot-busting” therapeutic for almost two decades to treat prevalent conditions such as pulmonary embolism, myocardial infarction and stroke. However, tPA may cause life-threatening hemorrhage, many patients’ clots are resistant to its action, and it is useful only within a few hours after the onset of symptoms. Frank’s lab has discovered that proteins not considered within the current fibrinolysis parad igm enhance tPA function in the vicinity of the clot. Frank’s research will further elucidate this auxiliary cofactor mechanism and the role of these proteins in fibrinolysis. This knowledge will be used in the development of novel clot-busting agents with enhanced safety and efficacy in comparison with existing medicines.
Outside the lab, Frank has been involved in a variety of musical pursuits including singing for a university rock band and for the UBC Faculty of Medicine acapella and choir groups. He also enjoys playing basketball, ultimate frisbee, and powerlifting.
In addition to the Vanier Scholarship, Frank has also been recognized by winning several other awards which include:
January 2, 2016
April 25, 2014
The Pathology & Laboratory Medicine graduate program in the Department of Pathology & Laboratory Medicine has received the 2013-14 Peter Larkin Award from the UBC Office of the Vice-President, Students.
The Peter Larkin Award is granted to a graduate program or department that has contributed to student development in honour of his commitment and passion for teaching and graduate education. The award is one of the UBC Student Development Awards that are awarded annually by the Office of the Vice-President, Students.
The Pathology & Laboratory Medicine graduate program trains students with varied backgrounds in science and medicine including: biochemistry, physiology, cell biology and microbiology/immunology. The program offers three degree programs: Master of Science, Doctor of Philosophy and combined Doctor of Medicine/Doctor of Philosophy.
Haydn Pritchard, a Professor in the Department of Pathology & Laboratory Medicine, is the program’s Graduate Advisor and Aleya Abdullah is the Graduate Program Assistant.
January 1, 2016
Once again, one of our students in the PALM graduate program has won a Vanier scholarship. These are highly competitive awards funded by the Government of Canada. The Vanier Canada Graduate Scholarships program “attracts and retains world-class doctoral students and helps establish Canada as a global centre of excellence in research and higher learning”. It is truly an honor for Jennifer and our program to have her achievements recognized in this manner.
Jennifer is a MD/PhD student mentored by Dr. David Huntsman. Her thesis project focuses on the metabolomic and proteomic characterization of ovarian clear cell carcinomas.
Ovarian cancer is the leading cause of cancer death for women, with about 25,000 women diagnosed in North America each year. Ovarian cancer is subdivided into different groups or ‘subtypes’, according to molecular characteristics and clinical outcome. Clear cell ovarian cancer (CCC) is the second most common subtype of ovarian cancer affecting many women. At late stage, it is more aggressive and resistant to current chemotherapy compared to other subtypes. Molecular and genomic studies suggest that it is a metabolically driven malignancy, but its metabolic profile has not yet been studied. It may be possible to develop CCC-specific therapy through targeting this subtype’s metabolic defects. Jennifer’s research will be the first characterization of a large cohort of clinical cases of CCC using protein expression in conjunction with global metabolite profiling. She hopes that identifying targetable metabolic pathways will guide the development of more effective therapies to help patients with this deadly disease.
Outside of the lab, Jennifer enjoys painting. She is the illustrator for the reading bear society, an non-profit organization working towards increasing childhood literacy especially for underprivileged children (http://thereadingbear.ca). Jennifer also enjoys nature and is the proud owner of many plants.
Jennifer’s other awards include:
Well done Jennifer!